Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study

Lung Cancer 2026 Open access

Read full text
Authors: Jean‐Baptiste Assié, Laurent Greillier, Aurélien Gobert, Lionel Falchero, Lise Thibonnier, Matthieu Chasseray, Christine Raynaud, Hugo Picchi, Thierry Chatellier, Romain Corre, Olivier Molinier, Alain Bakebe
+16 more Charles Naltet, Fleur-Marie Quillot, Laurene Gavoille, Thomas Pierret, Jean‐Marc Dot, Marie Wislez, Marielle Sabatini, Marie Tiercin, Gérard Zalcman, Ophélie Cassuto, Rémy Largillier, Anne Madroszyk, Nadia Munsch, Eric Pichon, Charles Ricordel, Olivier Bylicki
DOI: 10.1016/j.lungcan.2026.109622
Cited by: 1
References: 15

Fields of Study & Subjects

Occupational and environmental lung diseases Cancer Immunotherapy and Biomarkers Pleural and Pulmonary Diseases

Publication details

Journal / source
Lung Cancer
Publisher
Elsevier BV
Volume
221
Pages
109622–109622
Publication date
8 September 2026
Language
EN